Compare Gold Fields Limited (GFI) vs Moderna, Inc. (MRNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gold Fields Limited vs Moderna, Inc. — how do they compare? Gold Fields Limited trades at $32.14 (market cap $29.07B), while Moderna, Inc. trades at $64.38 (market cap $27.09B). The key difference: Gold Fields Limited and Moderna, Inc. are close in size by market cap, and Gold Fields Limited pays a 7.03% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals.
| GFI | MRNA | |
|---|---|---|
Market Cap | $29.07B | $27.09B |
Sector | Basic Materials | Health |
52-Week High | $61.52 | $81.80 |
52-Week Low | $23.95 | $22.36 |
Enterprise Value | $30.51B | $23.19B |
Dividend Yield | 7.03% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gold Fields (GFI) trades at $32.28, down 3.15% today, amid a bearish technical signal despite strong fundamentals. The stock shows robust profitability with a 40.76% net income margin and 52.33% ROE, while valuation ratios like P/E of 8.37 suggest undervaluation. Recent earnings were mixed, with a Q1 2025 beat but Q2 and Q4 2025 misses, and cash flow trends improved significantly in 2025 projections. News highlights operational challenges from inflation and geopolitical factors, though long-term value arguments persist.
The outlook balances deep value against near-term headwinds. Analyst consensus leans bullish with a $52.75 price target, but technical weakness and cost pressures pose risks. Investment appeal hinges on execution of production targets and gold price stability, with high ROE supporting shareholder returns.
Moderna (MRNA) trades at $64.11, down 4.94% over 24 hours, with a bullish technical outlook but mixed fundamentals. The company reported a net loss of -$2.82B in 2025 despite beating EPS estimates in recent quarters. Recent news highlights progress in oncology trials and an EU RSV vaccine contract, fueling investor optimism about pipeline expansion beyond COVID-19 vaccines.
Outlook: Long-term growth depends on successful pipeline commercialization, but high cash burn and negative margins pose risks. Analyst consensus is cautious with a $49 price target, suggesting 23.6% downside. Investors should weigh clinical successes against persistent profitability challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gold Fields Limited
Gold Fields Ltd is a producer of gold and is a holder of gold reserves and resources in South Africa, Ghana, Australia and Peru. In Peru, the company also produces copper. The company is primarily involved in underground and surface gold and surface copper mining and silver and related activities, including exploration, extraction, processing and smelting. It conducts underground and surface mining operations at St. Ives, underground-only operations at Agnew, Granny Smith and South Deep and surface-only open pit mining at Damang, Tarkwa and Cerro Corona. The company's revenues are derived from the sale of gold that it produces.
Read more on GFI →About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →
